Sibeprenlimab-szsi: A Breakthrough in IgA Nephropathy Treatment

Sibeprenlimab-szsi: Redefining IgA Nephropathy Care

Primary IgA nephropathy (IgAN) is one of the most common causes of chronic kidney disease worldwide. Despite optimized supportive care—such as blood pressure control, renin–angiotensin system blockade, and SGLT2 inhibitors—many patients continue to experience persistent proteinuria, a major risk factor for disease progression.

Sibeprenlimab-szsi (Voyxact; Otsuka) represents a new frontier in IgAN treatment. Approved by the FDA in November 2025 under accelerated approval, it is indicated for adults with primary IgAN who remain at risk despite standard therapy. Its approval was based on interim phase 3 trial data showing a significant reduction in proteinuria compared to placebo.

What makes sibeprenlimab unique is its mechanism of action. It is a first-in-class monoclonal antibody that targets APRIL, a cytokine responsible for abnormal IgA production. By neutralizing APRIL, sibeprenlimab reduces galactose-deficient IgA1 (Gd-IgA1), the key driver of immune complex formation and kidney damage. This upstream approach sets it apart from therapies that focus on downstream inflammation or hemodynamic effects.

Clinical data are encouraging. In the VISIONARY trial, patients receiving sibeprenlimab experienced about a 51% placebo-adjusted reduction in proteinuria at nine months, even when already on supportive therapies. While this reduction is clinically meaningful, confirmatory data on long-term kidney function preservation are still pending.

Safety remains a critical consideration. The most common side effects include upper respiratory tract infections and injection-site reactions. Patients must avoid live vaccines during treatment, and monitoring for infections is essential. Additionally, about one-third of patients developed antidrug antibodies, which may reduce drug effectiveness in some cases.

Sibeprenlimab is administered as a 400 mg subcutaneous injection every four weeks, offering convenience for patients who prefer a monthly dosing schedule. Pharmacists play a vital role in ensuring safe use—educating patients on injection techniques, monitoring proteinuria, and reinforcing supportive care measures.

In the evolving landscape of IgAN therapies, sibeprenlimab expands treatment options with a novel immunologic approach. While its long-term impact on kidney function is not yet confirmed, it provides hope for patients struggling with persistent proteinuria and highlights the growing importance of targeted therapies in nephrology.